Early treatment study
et al., medRxiv, doi:10.1101/2020.07.16.20155531 (Preprint) (not included in the study count)
Safety of Hydroxych loroquine among Outpatient Clinical Trial Participants for COVID-19
Analysis of 2,795 outpatients not showing significant safety concerns with HC Q. No deaths were related to HC Q. There was one serious event requiring hospitalization, identical to the frequency with placebo.
Please send us corrections, updates, or comments.